Mafune K I, Tanaka Y, Suda Y, Izumo T
Division of Abdominal Surgery Saitama Cancer Center Hospital, Japan.
Gastric Cancer. 2001;4(3):137-43. doi: 10.1007/pl00011736.
The best treatment for patients with non-Hodgkin's lymphoma (NHL) of the stomach is still uncertain. The revised European-American lymphoma (REAL) classification has helped to define new, potentially more appropriate classification schemes for gastric lymphomas.
Fifty-one resected gastric lymphomas were reclassified according to the REAL classification, and the efficacy of multimodal treatment was examined retrospectively. The principal treatment plan consisted of: (1) surgical resection of the stomach with lymph node dissection, followed by (2) systemic chemotherapy, mainly using the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen.
According to the Ann Arbor classification, 27 patients had stage IE, 19 had stage IIE, and 5 had stage IV NHL. Using the REAL classification, we diagnosed diffuse large B-cell lymphoma (DLBL) in 23 patients, marginal zone B-cell (low-grade mucosa-associated lymphoid tissue [MALT]-type) lymphoma in 22, follicle center lymphoma in 4, mantle cell lymphoma in 1, and peripheral T-cell lymphoma in 1 patient. Nine of the 51 patients relapsed, and 8 patients with DLBL died of cancer. Survival rates at 5 years after surgery were 96.0% for stage IE, 83.3% for stage IIE, and 87.0% for all patients. Univariate analysis indicated that the tumor histology (according to the REAL classification), depth of invasion, degree of nodal involvement, Ann Arbor staging, and chemotherapy had an impact on patient outcome (P = 0.0018; P = 0.0002; P = 0.0308; P = 0.0016, and P = 0.0118, respectively).
These data reveal that gastric NHL, especially of the low-grade MALT-type, often remains localized and has a good prognosis after surgery. The REAL classification was useful for classifying new categories of NHL, including the MALT-type, in the clinical setting, and for determining the optimal treatment modality for gastric NHL.
胃非霍奇金淋巴瘤(NHL)患者的最佳治疗方案仍不明确。修订后的欧美淋巴瘤(REAL)分类有助于为胃淋巴瘤定义新的、可能更合适的分类方案。
根据REAL分类对51例切除的胃淋巴瘤进行重新分类,并回顾性研究多模式治疗的疗效。主要治疗方案包括:(1)胃切除及淋巴结清扫术,随后(2)全身化疗,主要采用环磷酰胺/阿霉素/长春新碱/泼尼松(CHOP)方案。
根据Ann Arbor分类,27例患者为IE期,19例为IIE期,5例为IV期NHL。采用REAL分类,我们诊断出23例弥漫性大B细胞淋巴瘤(DLBL),22例边缘区B细胞(低级别黏膜相关淋巴组织[MALT]型)淋巴瘤,4例滤泡中心淋巴瘤,1例套细胞淋巴瘤,1例外周T细胞淋巴瘤。51例患者中有9例复发,8例DLBL患者死于癌症。IE期患者术后5年生存率为96.0%,IIE期为83.3%,所有患者为87.0%。单因素分析表明,肿瘤组织学(根据REAL分类)、浸润深度、淋巴结受累程度、Ann Arbor分期和化疗对患者预后有影响(P分别为0.0018;P = 0.0002;P = 0.0308;P = 0.0016和P = 0.0118)。
这些数据表明,胃NHL,尤其是低级别MALT型,通常局限于局部,手术后预后良好。REAL分类有助于在临床环境中对包括MALT型在内的新的NHL类别进行分类,并确定胃NHL的最佳治疗方式。